Risk of Peptic Ulcer Hospitalizations in Users of NSAIDs With Gastroprotective Cotherapy Versus Coxibs

Gastroenterology

Volumn 133, Issue 3, 2007, Pages 790-798

  Ray, Wayne A ^a,b   Chung, Cecilia P ^a   Stein, C Michael ^a   Smalley, Walter E ^a,b   Hall, Kathi ^a   Arbogast, Patrick G ^a   Griffin, Marie R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Veterans Administration Tennessee Valley Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CIMETIDINE; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROFECOXIB; TICLOPIDINE; VALDECOXIB; ANTIULCER AGENT; PROTON PUMP;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAID; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH DISEASE; TIME SERIES ANALYSIS; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GASTROINTESTINAL TRACT; MIDDLE AGED; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; STATISTICS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL TRACT; HISTAMINE H2 ANTAGONISTS; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOARTHRITIS; PEPTIC ULCER; PROTON PUMPS; RISK FACTORS;

EID: 34548497097     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.06.058     Document Type: Article

References (43)

1. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
2. Hernandez-Diaz S., and Garcia-Rodriguez L.A. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 110 (2001) 20S-27S
3. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
4. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 93 (1998) 2037-2046
5. MacLean C.H. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 135 (2001) 711-721
6. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celocoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
7. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
8. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
9. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1-11
10. Solomon S.D., McMurray J.J.V., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1-10
11. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 11
12. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
13. Rostom A, Wells G, Tugwell P, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2000;(4):CD002296. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD002296.
14. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
15. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management. N Engl J Med 338 (1998) 727-734
16. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334 (1996) 1435-1439
17. Smalley W., Stein C.M., Arbogasts P.G., et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal anti-inflammatory drugs. Arthritis Rheum 46 (2002) 2195-2199
18. Abraham N.S., El-Serag H.B., Johnson M.L., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129 (2005) 1171-1178
19. Laine L., Curtis S.P., Cryer B., et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369 (2007) 465-473
20. Chan F.K.L., Hung L.C.T., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
21. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
22. Ray W.A., and Griffin M.R. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 129 (1989) 837-849
23. Ruther M., Pagan B.A., Rinkle V., et al. Program statistics: Medicare and Medicaid data book, 1984 (1996), Health Care Financing Administration, Baltimore, MD
24. Ray W.A. Population-based studies of adverse drug effects. N Engl J Med 349 (2003) 1592-1594
25. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158 (2003) 915-920
26. Landry J.A., Smyer M.A., Tubman J.G., et al. Validation of two methods of data collection of self-reported medicine use among the elderly. Gerontologist 28 (1988) 672-676
27. West S.L., Savitz D.A., Koch G., et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142 (1995) 1103-1110
28. Johnson R.E., and Vollmer W.M. Comparing sources of drug data about the elderly. J Am Geriatr Soc 39 (1991) 1079-1084
29. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114 (1991) 257-263
30. Smalley W.E., Ray W.A., Daugherty J., et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Intern Med 159 (1999) 161-166
31. Griffin M.R., Yared A., and Ray W.A. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 151 (2000) 488-496
32. Hawkey C.J., Farkouh M., Gitton X., et al. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib-study design and patient demographics. Aliment Pharmacol Ther 20 (2004) 51-63
33. de Boer W.A., and Tytgat G.N.J. Regular review: treatment of Helicobacter pylori infection. BMJ 320 (2000) 31-34
34. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
35. Sturmer T., Schneeweiss S., Brookkhart M.A., et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 161 (2005) 891-898
36. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 719-726
37. Höer A., Gothe H., Schiffhorst G., et al. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf 16 (2007) 854-858
38. García-Rodríguez L.A., and Tolosa L.B. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 (2007) 498-506
39. Lanus A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
40. Henry D., L-Y Lim L., Garcia Rodriguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 312 (1996) 1563-1566
41. Chan F.K.L., Wong V.W.S., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
42. Rothman K.J., and Greenland S. Modern epidemiology. 2nd ed. (1998), Lippincott-Raven, Philadelphia, PA
43. Brenner H., Arndt V., Gefeller O., et al. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer 40 (2004) 2317-2322